» Articles » PMID: 27761767

Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care

Overview
Publisher Springer
Specialty General Medicine
Date 2016 Oct 21
PMID 27761767
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Since FDA approval of HIV pre-exposure prophylaxis (PrEP) for HIV prevention, attention has been focused on PrEP implementation. The CDC estimates that 1.2 million U.S. adults might benefit from PrEP, but only a minority are using PrEP, so there is a significant unmet need to increase access for those at risk for HIV. Given the large numbers of individuals who have indications for PrEP, there are not enough practicing specialists to meet the growing need for providers trained in providing PrEP. Moreover, since PrEP is a preventive intervention for otherwise healthy individuals, primary care providers (PCPs) should be primary prescribers of PrEP. There are important clinical considerations that providers should take into account when planning to prescribe PrEP, which are highlighted in the clinical case discussed. A growing body of research also suggests that some providers may be cautious about prescribing PrEP because of concerns regarding its "real-world" effectiveness, anticipated unintended consequences associated with its use, and ambiguity as to who should prescribe it. This review summarizes findings from studies that have assessed prescriber behavior regarding provision of PrEP, and offers recommendations on how to optimize PrEP implementation in primary care settings. Development and dissemination of educational interventions for PCPs and potential PrEP users are needed, including improved methods to assist clinicians in identifying appropriate PrEP candidates, and programs to promote medication adherence and access to social and behavioral health services. PCPs are well-positioned to prescribe PrEP and coordinate health-related services to improve the sexual health of their patients, but tailored educational programs are needed.

Citing Articles

Assessing Knowledge, Practices, and Barriers to PrEP and nPEP Prescription Among Texas Healthcare Providers.

Tiruneh Y, Rachmale R, Elerian N, Lakey D Healthcare (Basel). 2024; 12(22).

PMID: 39595512 PMC: 11593935. DOI: 10.3390/healthcare12222315.


Factors influencing the implementation of a guideline for re-engagement in HIV care in primary care settings in Johannesburg, South Africa: A qualitative study.

Makina-Zimalirana N, Wilkinson L, Grimsrud A, Davies N, Mutyambizi C, Jiyane A PLOS Glob Public Health. 2024; 4(10):e0003765.

PMID: 39475838 PMC: 11524482. DOI: 10.1371/journal.pgph.0003765.


Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study.

Rael C, Das D, Porter J, Lopez-Rios J, Abascal E, Dolezal C J Assoc Nurses AIDS Care. 2024; 35(5):437-449.

PMID: 39137316 PMC: 11361836. DOI: 10.1097/JNC.0000000000000488.


Leveraging A Digital Pill System to Understand Prevention-Effective Adherence to Oral Hiv Pre-Exposure Prophylaxis Among Men Who Have Sex with Men with Substance Use.

Chai P, Goodman G, Mohamed Y, Bustamante M, Albrechta H, Lee J AIDS Behav. 2024; 28(10):3373-3380.

PMID: 38985403 PMC: 11427137. DOI: 10.1007/s10461-024-04435-7.


High Rates of Missed HIV Testing Among Oral PrEP Users in the United States From 2018-2021: A National Assessment on Compliance With HIV Testing Recommendations of the CDC PrEP Guidelines.

Baron J, Tchelidze T, LaBrot B, Yao J, Mayer K, Kuritzkes D Open Forum Infect Dis. 2024; 11(5):ofae254.

PMID: 38798900 PMC: 11127479. DOI: 10.1093/ofid/ofae254.


References
1.
Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

2.
Spinner C, Boesecke C, Zink A, Jessen H, Stellbrink H, Rockstroh J . HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2015; 44(2):151-8. DOI: 10.1007/s15010-015-0850-2. View

3.
Mulligan K, Glidden D, Anderson P, Liu A, McMahan V, Gonzales P . Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis. 2015; 61(4):572-80. PMC: 4565984. DOI: 10.1093/cid/civ324. View

4.
Grant P, Cotter A . Tenofovir and bone health. Curr Opin HIV AIDS. 2016; 11(3):326-32. PMC: 4844450. DOI: 10.1097/COH.0000000000000248. View

5.
Horberg M, Raymond B . Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance. Am J Prev Med. 2012; 44(1 Suppl 2):S125-8. DOI: 10.1016/j.amepre.2012.09.039. View